We serve Chemical Name:(r)-(+)-2,2′,6,6′-tetramethoxy-4,4′-bis(diphenylphosphino)-3,3′-bipyridine CAS:362524-23-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(r)-(+)-2,2′,6,6′-tetramethoxy-4,4′-bis(diphenylphosphino)-3,3′-bipyridine
CAS.NO:362524-23-0
Synonyms:DL-2-Dimethylamino-3-phenyl-propan-1-ol;N,N-DIMETHYL-3-PHENYL-3-HYDROXY PROPYLAMINE;2-dimethylamino-3-phenyl-1-propanol;MFCD04038734;3-DIMETHYLAMINO-1-PHENYL-PROPAN-1-OL
Molecular Formula:C38H34N2O4P2
Molecular Weight:644.63500
HS Code:
Physical and Chemical Properties:
Melting point:261-265ºC
Boiling point:686.1ºC at 760mmHg
Density:N/A
Index of Refraction:
PSA:89.88000
Exact Mass:644.19900
LogP:5.69440
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like DL-2-Dimethylamino-3-phenyl-propan-1-ol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-DIMETHYLAMINO-1-PHENYL-PROPAN-1-OL physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-dimethylamino-3-phenyl-1-propanol Use and application,2-dimethylamino-3-phenyl-1-propanol technical grade,usp/ep/jp grade.
Related News: For skin rash, the difference in response rates for anifrolumab versus placebo at week 52 were 13.5% SLE Disease Activity Index (SLEDAI), 15.5% British Isles Lupus Assessment Group index (BILAG) and 15.6% modified Cutaneous Lupus Erythematosus Disease Area and Severity Index (mCLASI). For arthritis, differences in response rates were 8.2% SLEDAI, 11.8% BILAG and 12.6% joint response. 4,4′-Dichloro-3,3′-dinitrodiphenylmethane manufacturers It’s official. Nearly two years after the FDA granted conditional approval to Merck’s Keytruda and Eisai’s Lenvima for endometrial cancer, the U.S. regulator has blessed the combination therapy, with no strings attached. Boc-Val-Val-Arg(NO2)-OBzl suppliers “We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab,” Sandrock said. “A better understanding of the facts is good for everyone involved to assure confidence in both the therapy and the process by which it was approved as we prioritize the issues that affect patients.” 1-(carbomethoxy)-2-deoxy-3,5-di-O-p-toluoyl-β-D-erythropentofuranose vendor & factory.
